Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates
- 13 February 2008
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 26 (7), 947-955
- https://doi.org/10.1016/j.vaccine.2007.11.087
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 ofBacillus anthracisprotective antigenFEMS Immunology & Medical Microbiology, 2006
- Direct Inhibition of T-Lymphocyte Activation by Anthrax Toxins In VivoInfection and Immunity, 2005
- Combining Anthrax Vaccine and Therapy: a Dominant-Negative Inhibitor of Anthrax Toxin Is Also a Potent and Safe Immunogen for VaccinesInfection and Immunity, 2005
- Structure of heptameric protective antigen bound to an anthrax toxin receptor: A role for receptor in pH-dependent pore formationProceedings of the National Academy of Sciences, 2004
- Crystal structure of a complex between anthrax toxin and its host cell receptorNature, 2004
- A dually active anthrax vaccine that confers protection against both bacilli and toxinsProceedings of the National Academy of Sciences, 2003
- Dominant-Negative Mutants of a Toxin Subunit: An Approach to Therapy of AnthraxScience, 2001
- Involvement of Domain 3 in Oligomerization by the Protective Antigen Moiety of Anthrax ToxinJournal of Bacteriology, 2001
- Discovery of the anthrax toxin: the beginning of in vivo studies on pathogenic bacteriaTrends in Microbiology, 2000
- Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal anti bodiesMicrobiology, 1996